Unicycive announces FDA acceptance of NDA for OLC
Unicycive's oxylanthanum carbonate (OLC) NDA was accepted by the FDA with a PDUFA date of March 25, 2027. The development of this kidney disease treatment marks a significant regulatory milestone for the biotechnology company.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed